Glass House Brands (GLAS) Change in Receivables (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Change in Receivables of -$2.1 million for Q1 2026, down 47.19% year-over-year from -$4.0 million in Q1 2025, and down 239.36% quarter-over-quarter from $1.5 million in Q4 2025.
Glass House Brands (GLAS) Change in Receivables (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Change in Receivables for 7 consecutive years, with -$2.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 47.19% year-over-year to -$2.1 million; the TTM figure through Mar 2026 stood at -$125000.0 (up 86.47% YoY), while the FY2025 annual figure was $547000.0, down 63.07% from the prior year.
- Change in Receivables eased to -$2.1 million in Q1 2026 per GLAS's latest filing, from $1.5 million in the prior quarter.
- Across five years, Change in Receivables topped out at $5.6 million in Q4 2024 and bottomed at -$4.9 million in Q2 2024.
- Historically, Change in Receivables has averaged $21259.8 across 5 years, with a median of $277000.0 in 2022.
- Annual changes were most pronounced in 2022 — Change in Receivables plunged 2147.95% — and 2024, when it surged 3267.94%.
- Glass House Brands' Change in Receivables stood at $842000.0 in 2022, then tumbled by 80.2% to $166719.0 in 2023, then soared by 3267.94% to $5.6 million in 2024, then slumped by 73.21% to $1.5 million in 2025, then slumped by 239.36% to -$2.1 million in 2026.
- Business Quant data shows GLAS's Change in Receivables at -$2.1 million in Q1 2026, $1.5 million in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Glass House Brands | 837.25 Mn | 818.69 Mn | 15.77 Mn | -3.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.10 Mn |
| Mar 31, 2026 | -2.10 Mn |
| Dec 31, 2025 | 1.50 Mn |
| Dec 31, 2025 | 1.50 Mn |
| Sep 30, 2025 | 3.72 Mn |
| Sep 30, 2025 | 3.72 Mn |
| Jun 30, 2025 | -3.25 Mn |
| Jun 30, 2025 | -3.25 Mn |
| Mar 31, 2025 | -1.42 Mn |
| Mar 31, 2025 | -1.42 Mn |
| Dec 31, 2024 | 5.62 Mn |
| Dec 31, 2024 | 5.62 Mn |
| Sep 30, 2024 | -251,000.00 |
| Sep 30, 2024 | -251,000.00 |
| Jun 30, 2024 | -4.86 Mn |
| Jun 30, 2024 | -4.86 Mn |
| Mar 31, 2024 | 981,000.00 |
| Mar 31, 2024 | 981,000.00 |
| Dec 31, 2023 | 166,719.00 |
| Dec 31, 2023 | 166,719.00 |